Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Graff

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
AIDS (London, England)|October 1, 1990
Performance characteristics of a novel immunoassay based on hybrid Ty virus-like particles (Ty-VLPs): rapid differentiation between HIV-1 and HIV-2 infectionJ E Gilmour, S J Read, R Eglin, et al.
Neurology|September 17, 1999
Pathologic heterogeneity in clinically diagnosed corticobasal degenerationB F Boeve, D M Maraganore, J E Parisi, et al.
Frontiers in Oncology|August 28, 2020
Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation TherapyJulie N Graff, Mark N Stein, Rishi Surana, et al.
Journal of Surgical Education|October 21, 2015
A Disease-Specific Hybrid Rotation Increases Opportunities for Deliberate PracticeMackenzie R Cook, Amanda N Graff-Baker, Alexis M Moren, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineagesYa-Mei Hu, Faming Zhao, Julie N Graff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILJ N Graff, G Baciarello, A J Armstrong, et al.
Oncotarget|July 19, 2016
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancerJulie N Graff, Joshi J Alumkal, Charles G Drake, et al.
Neurology|July 11, 2007
A plateau in pre-Alzheimer memory decline: evidence for compensatory mechanisms?G E Smith, V S Pankratz, S Negash, et al.
Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancerC N Sternberg, F Saad, J N Graff, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
AIDS (London, England)|October 1, 1990
Performance characteristics of a novel immunoassay based on hybrid Ty virus-like particles (Ty-VLPs): rapid differentiation between HIV-1 and HIV-2 infectionJ E Gilmour, S J Read, R Eglin, et al.
Neurology|September 17, 1999
Pathologic heterogeneity in clinically diagnosed corticobasal degenerationB F Boeve, D M Maraganore, J E Parisi, et al.
Frontiers in Oncology|August 28, 2020
Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation TherapyJulie N Graff, Mark N Stein, Rishi Surana, et al.
Journal of Surgical Education|October 21, 2015
A Disease-Specific Hybrid Rotation Increases Opportunities for Deliberate PracticeMackenzie R Cook, Amanda N Graff-Baker, Alexis M Moren, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineagesYa-Mei Hu, Faming Zhao, Julie N Graff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILJ N Graff, G Baciarello, A J Armstrong, et al.
Oncotarget|July 19, 2016
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancerJulie N Graff, Joshi J Alumkal, Charles G Drake, et al.
Neurology|July 11, 2007
A plateau in pre-Alzheimer memory decline: evidence for compensatory mechanisms?G E Smith, V S Pankratz, S Negash, et al.
Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancerC N Sternberg, F Saad, J N Graff, et al.
Pageof 12